You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 63 No. 5, May 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (5)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Stroke
 •Alert me on articles by topic

Venturi Mask Adjuvant Oxygen Therapy in Severe Acute Ischemic Stroke

Elley H. H. Chiu, MD; Chin-San Liu, MD, PhD; Teng-Yeow Tan, MD; Ku-Chou Chang, MD

Arch Neurol. 2006;63:741-744.

Background  The effect of oxygen therapy in acute ischemic stroke remains undetermined.

Objective  To investigate the feasibility of eubaric hyperoxia therapy by Venturi mask (VM) in a group of patients who experienced a severe acute ischemic stroke.

Design  Patients experiencing a first-ever large middle cerebral artery infarction were recruited within 48 hours after stroke. Patients were subdivided to undergo therapy with a VM with a fraction of inspired oxygen of 40% or with a nasal cannula. A large middle cerebral artery infarction was defined as a large low-attenuation area of more than one third of the middle cerebral artery territory on brain images. Stroke severity was evaluated by the National Institutes of Health Stroke Scale.

Results  Seventeen patients were enrolled in the VM group and 29 in the nasal cannula group. All the demographic and clinical characteristics were equally distributed initially. The mean initial National Institutes of Health Stroke Scale score was 20.5 and 18.9 in the VM and nasal cannula groups, respectively. Atrial fibrillation was found in 11 (65%) patients in the VM and 17 (59%) patients in the nasal cannula groups. The VM therapy was initiated within 13.7 (range, 3.0-41.5) hours after stroke and the duration was 132.9 (range, 48.0-168.5) hours. In-hospital mortality was 1 (6%) in the VM group and 7 (24%) in the nasal cannula group (P=.12). In the VM group, there were fewer incidences of fever (4 [24%] vs 15 [52%]; P=.06), pneumonia (1 [6%] vs 6 [21%]; P=.18), and respiratory failure (3 [18%] vs 8 [28%]; P=.45), but a higher incidence of bedsores (3 [18%] vs 2 [7%]; P=.29).

Conclusions  By using VM therapy with a fraction of inspired oxygen of 40%, there might be less mortality and comorbidities in treated patients who experienced a severe acute ischemic stroke. Further randomized confirmatory studies should explore the decreased mortality in patients who experience a severe acute ischemic stroke, especially in those with a large middle cerebral artery infarction who undergo VM therapy with a fraction of inspired oxygen of 40%.


Author Affiliations: Division of Acupuncture (Dr Chiu), Departments of Traditional Chinese Medicine (Dr Chiu) and Neurology (Drs Chiu, Tan, and Chang), Chang Gung Memorial Hospital, Kaohsiung; College of Medicine, Chang Gung University, Taoyuan (Drs Tan and Chang); Department of Neurology and Vascular and Genomic Research Center, Changhua Christian Hospital, Changhua (Dr Liu); and Department of Neurology, Chung Shan Medical University and Chung Shan Medical University Hospital, Taichung (Dr Liu), Taiwan.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Advances in Emerging Nondrug Therapies for Acute Stroke 2007
Singhal and Lo
Stroke 2008;39:289-291.
FULL TEXT  

Normobaric hyperoxia improves cerebral blood flow and oxygenation, and inhibits peri-infarct depolarizations in experimental focal ischaemia
Shin et al.
Brain 2007;130:1631-1642.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.